Unstable Angina Pectoris Clinical Trial
Official title:
A Randomized, Double-blind, Multicenter, Parallel Controlled Clinical Trial of Danhong Injection in the Treatment of Unstable Angina Pectoris
Verified date | November 2017 |
Source | China Academy of Chinese Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the efficacy and safety of Danhong injection in the treatment of unstable angina pectoris.
Status | Completed |
Enrollment | 160 |
Est. completion date | November 2017 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Female or male inpatients. - Age: 35 - 75 years. - Patients with clinical diagnosis of unstable stable angina according to China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association, including one of the following conditions. - Clinical diagnosis of "Xueyu Zheng" (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of "Xueyu Zheng" in UA = 15. The Chinese medicine symptoms scales of "Xueyu Zheng" is a 6-item questionnaire including the symtoms as following: (1)chest pain-10, (2)chest distress-10, (3) palpitation-5, (4)purple or dark lip-5, (5) purple or dark tongue-5, (6) unsmooth pulse-5. - Patient is willing to participate voluntarily and to sign a written patient informed consent. Exclusion Criteria: - Patients with severe heart failure (EF<35%); - Patients with history of infection, fever, trauma, surgery(exclude PCI) and inflammation in the past month; - Patients with active tuberculosis or rheumatological disorders; - Patients with renal dysfunction (Male: CCr>2.5mg/dl; Female: CCr>2.0mg/dl); - Patients with liver dysfunction (any value of serum aminotransferase more than triple normal value); - Patients with history of hematopoietic system diseases; - Patients with mental disorder; - Patients with history of drug-induced bleeding or history of bleeding caused by warfarin; - Patients with malignant tumor; - Patients with history of organ transplant; - Woman with pregnancy, lactation or positive result of pregnancy test; - Patients who is participating in other trials or has been participated in other trials in recent 3 months; - Patients who were unable to participate in the study as judged by investigator. |
Country | Name | City | State |
---|---|---|---|
China | Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine | Beijing | Beijing |
China | Xuanwu Hospital | Beijing | Beijing |
China | The Affiliated Hospital to Changchun University of Chinese Medicine | Changchun | Jilin |
China | The First Hospital of Changsha | Changsha | Hunan |
China | The First Affiliated Hospital of Guangzhou University of Chinese Medicine | Guangzhou | Guangdong |
China | The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine | Ha'erbin | Heilongjiang |
China | Hospital 463 of P.L.A. | Shenyang | Liaoning |
China | First Teaching Hospital of Tianjin University of T.C.M. | Tianjin | Tianjin |
China | Zhengzhou No.7 People's Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
China Academy of Chinese Medical Sciences | China Food and Drug Administration |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline of the Quantification score of angina pectoris at Day 7 | Quantification score of angina pectoris is a 4-item questionnaire that quantifies the frequency of angina, the duration of angina at every attack, the severity of angina and the use of nitroglycerin in a week. Scores range from 0 to 24; higher scores indicate worse health status. | Day 7 | |
Secondary | Total score of symptoms questionnaire of TCM | The symptoms questionnaire of TCM consists of 6 symptoms that described in traditional Chinese medicine, including chest pain, chest distress, palpitation, dark-purple lip, dark-purple tongue and unsmooth pulse. Each symptom was assessed by the Visual Analogue Scale(VAS),where a higher score meant higher severity. | Day 0, Day 7 | |
Secondary | Use of Short-acting Nitrates | Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 28 | ||
Secondary | Change in the electrocardiogram (ECG) | ECG will be done five times every day, when 5-10 min before use of nitrates or Danhong injection, 5-10 min after use of nitrates or Danhong injection, at the time 22:00. If there is an angina attack, an additional ECG should be done when the angina attacks. | Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 28 | |
Secondary | The proportion of patients who are undergoing PCI | Day 7, Day 28 | ||
Secondary | Change in Seattle Angina Questionnaire | Seattle Angina Questionnaire, a 19-item questionnaire that quantifies physical limitations due to angina, any recent change in the severity of angina, the frequency of angina, satisfaction with treatment, and quality of life. Scores range from 0 to 100; higher scores indicate better health status.With a score of 20 or more on the angina-frequency scale indicating that the patient was clinically significant change. | Day 0, Day 28 | |
Secondary | Incidence of adverse events (including serious adverse events) in 28 days | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Completed |
NCT02612116 -
Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study
|
Phase 4 | |
Active, not recruiting |
NCT02508714 -
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
|
N/A | |
Completed |
NCT02939248 -
Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine
|
Phase 4 | |
Active, not recruiting |
NCT02175706 -
DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity
|
N/A | |
Completed |
NCT01377402 -
ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study
|
N/A | |
Completed |
NCT00521976 -
Risk Markers in the Acute Coronary Syndromes
|
||
Completed |
NCT02144090 -
Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study
|
N/A | |
Completed |
NCT00627744 -
Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction
|
Phase 4 | |
Completed |
NCT00990262 -
Rule Out Myocardial Infarction by Computer Assisted Tomography
|
N/A | |
Enrolling by invitation |
NCT04008173 -
The International Survey of Acute Coronary Syndromes-ARCHIVES
|
||
Withdrawn |
NCT02165670 -
BASIC VALIDATE Coronary Stent Registry
|
||
Completed |
NCT01293097 -
Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI
|
Phase 4 | |
Completed |
NCT01066650 -
The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente
|
Phase 4 | |
Completed |
NCT02747329 -
A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT
|
N/A | |
Completed |
NCT02939235 -
Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine
|
Phase 4 | |
Not yet recruiting |
NCT03155971 -
PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial)
|
N/A | |
Recruiting |
NCT04575207 -
The Flash FFR Ⅱ Study
|
N/A | |
Terminated |
NCT02235753 -
High-intensity Exercise After Acute Cardiac Event (HITCARE)
|
N/A | |
Completed |
NCT01752582 -
BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)
|
N/A |